Pneumonia: A Persistent Threat to Human Life and Its Economic Impact

Pneumonia remains one of the most serious infectious diseases worldwide, posing a significant threat to human health and placing a heavy burden on healthcare systems and economies. While community-acquired pneumonia is widely recognized, hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), represents a critical subset that demands attention due to its severity and preventability. Early detection is key to improving patient outcomes and reducing the overall impact of this disease.

The Human Toll of Pneumonia

Pneumonia is an infection that inflames the air sacs in one or both lungs, which can fill with fluid or pus, leading to cough, fever, chills, and difficulty breathing. Complications from pneumonia can be life-threatening, including respiratory failure requiring mechanical ventilation, sepsis (a critical bloodstream infection), and abscesses in or around the lungs that may need surgical intervention. Early detection and appropriate treatment are essential to minimize these risks.

While anyone can develop pneumonia, certain groups are especially vulnerable:

·      Older adults: Age-related decline in immune function makes seniors particularly susceptible. Complications can be severe, often requiring hospitalization and intensive care. Data from England and Wales showed over 2,200 deaths involved influenza or pneumonia in one week of February 2025, with pneumonia as the underlying cause in more than 800 cases.

·      Immunocompromised individuals and those with chronic illnesses: People with weakened immune systems or underlying health conditions face higher risks of severe disease and complications.

These vulnerable populations are not only more susceptible to community-acquired infections but also face heightened risks within healthcare settings. Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are particularly concerning for these groups, as their compromised health status makes them more prone to severe outcomes from such infections.

The Hidden Burden of Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP)

Hospital-acquired pneumonia (HAP), particularly ventilator-associated pneumonia (VAP), poses a significant challenge within healthcare settings. HAP occurs 48 hours or more after hospital admission and was not incubating at the time of admission, while VAP develops more than 48 hours after endotracheal intubation.

These infections are associated with increased morbidity and mortality. For instance, patients with HAP have hospital stays extended by 7–9 days on average, while VAP can extend stays by an additional 7–13 days. Mortality rates are substantial, with HAP reported at 20–30% and VAP even higher at 20–50%, depending on patient populations and comorbid conditions.

The economic impact is equally concerning. Treating HAP can cost between $28,000 to $40,000 per patient, while VAP treatment ranges from $40,000 to $60,000 per patient. Annually, the combined economic burden of HAP and VAP in the U.S. is estimated to exceed $10 billion, driven by prolonged hospital stays, increased ICU admissions, and extensive use of antibiotics and other therapeutic interventions. Beyond direct medical expenses, pneumonia leads to lost productivity, extended rehabilitation, and, in severe cases, long-term disability or death, further amplifying its societal cost.

These figures underscore the critical need for effective prevention strategies, early detection, and appropriate management of HAP and VAP to improve patient outcomes and reduce the strain on healthcare resources.

The Role of Rapid, Non-Invasive Diagnostics

Traditional diagnostic methods for pneumonia, such as chest X-rays and sputum cultures, can be time-consuming and may not always provide definitive results quickly. Rapid, non-invasive diagnostics, like breath analysis, offer a promising solution for faster and more accurate detection.

Breath analysis identifies volatile organic compounds (VOCs) in exhaled breath that are indicative of pneumonia. Our company's OneBreath™ system, for example, uses microreactor technology and liquid chromatography-mass spectrometry (LC-MS) to deliver results in under 10 minutes. This rapid analysis can help clinicians quickly differentiate between high- and low-risk patients, guiding appropriate treatment decisions that will save precious lives and reduce the financial as well as the capacity-related burdens to national health systems.

Recent collaborative research with the University of Louisville supports this approach: in a clinical study involving 75 patients undergoing elective cardiac surgery, machine learning models analyzing VOCs from exhaled breath achieved high accuracy in both diagnosing and predicting pneumonia onset. The diagnostic model demonstrated an AUROC (Area Under the Receiver Operating Characteristic Curve) of 0.881, while the predictive model—using only pre-operative breath samples—achieved an AUROC of 0.905. These findings underscore the powerful potential of breath-based diagnostics to identify at-risk patients early and enable proactive intervention strategies.

Conclusion

Pneumonia continues to be a formidable threat to global health, with devastating consequences for individuals and significant costs for healthcare systems. As populations age and antimicrobial resistance rises, the need for effective prevention, early detection, and innovative diagnostic tools—such as rapid, non-invasive breath analysis—has never been greater. By investing in prevention, embracing new technologies, and promoting early detection, we can reduce the burden of pneumonia and protect the most vulnerable among us.

References:

1.     CNN: Why respiratory infections are especially dangerous for older adults and children (https://edition.cnn.com/2025/02/19/health/pneumonia-virus-bacteria-older-adults-wellness/index.html#:~:text=Older%20individuals%20are%20more%20likely,diminished%20ability%20to%20fight%20infections.)

2.     Office for National Statistics: Deaths registered weekly in England and Wales, February 2025 (https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregisteredweeklyinenglandandwalesprovisional/weekending28february2025#:~:text=In%20the%20week%20ending%2028%20February%202025%20(Week%209)%2C,in%20Wales%20(Table%201).&text=Figures%20for%20%22England%20and%20Wales%22%20include%20non%2Dresidents.)

3.     Conference Board of Canada: Costs of Treating Pneumonia Will More Than Double By 2025 (https://www.newswire.ca/news-releases/costs-of-treating-pneumonia-will-more-than-double-by-2025-619026564.html)

4.     Locus Bio: The burden of hospital-acquired pneumonia and ventilator-associated pneumonia in the US (https://www.locus-bio.com/the-burden-of-hospital-acquired-pneumonia-hap-and-ventilator-associated-pneumonia-vap-in-the-us/)

‍